Expression and Clinical Significance of IGHD in Pancreatic Cancer
Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer.
Objective： To explore the expression of IGHD in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer.
Methods： In this study, qRT-PCR was used to detect IGHD expression in peripheral blood. The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.
Study Overview
Detailed Description
Methods：The expressions of IGHD in peripheral blood of about 30 patients with pancreatic cancer and more than 30 healthy controls were detected by qRT-PCR, and the differences of IGHD were analyzed.The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.
Pancreatic cancer is a disease of digestive system with a high degree of malignancy. The level of early diagnosis and therapeutic effect are limited by the research status of pancreatic adenocarcinoma. Conventional CT, MRI and other methods have a limited level of early diagnosis of pancreatic cancer, and EUS and endoscope-guided needle biopsy are in the stage of clinical trials. Studies on novel markers involve protein, miRNA, exosome, methylation, protein and genomics, but there is no mature and practical diagnostic method. Based on the current diagnosis, treatment and prognosis level of pancreatic cancer, I made a bold attempt to study the expression of IGHD in pancreatic cancer and their relationship with clinical parameters and prognosis level, so as to screen molecular markers conducive to diagnosis, treatment and prognosis of pancreatic cancer and provide data support for improving the diagnosis and treatment level of pancreatic cancer.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Lu Y Yuhua, phd
- Phone Number: China +86 13862815432
- Email: lyh76@126.com
Study Contact Backup
- Name: Chen Q QiYang, master
- Phone Number: China +86 18860970651
- Email: drcqy13@126.com
Study Locations
-
-
Jiangsu
-
Nantong, Jiangsu, China
- Recruiting
- The Affiliated Hospital of Nantong University
-
Contact:
- Lu Yuhua, phd
- Phone Number: +8613862815432
- Email: lyh76@126.com
-
Contact:
- Chen Qiyang, master
- Phone Number: +8618860970651
- Email: drcqy13@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with pathologically confirmed pancreatic cancer
Exclusion Criteria:
- noperable patients
- other malignant tumors
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
pancreatic cancer patients
pathologically confirmed pancreatic cancer patients
|
The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
|
|
healthy people
people without no neoplastic lesions and other organic diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
High expression of IGHD is independent risk factors for poor prognosis in patients with pancreatic cancer.
Time Frame: 2022.4-2023.10
|
IGHD was highly expressed in pancreatic cancer patients , but low in the healthy cancer-free patients. Patients with high expression of IGHD had lower prognosis. High expression of IGHD, T stage (T3T4), lymphatic metastasis and distant metastasis are independent risk factors for poor prognosis in patients with pancreatic cancer. Expression level of IGHD in peripheral blood cells is a potential biomarker for the diagnosis of pancreatic cancer |
2022.4-2023.10
|
Collaborators and Investigators
Investigators
- Study Director: Lu Y Yuhua, phd, The Affiliated Hospital of Nantong University
- Principal Investigator: Chen Q Qiyang, master, Nantong University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTlyh76
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.